Prolactin response to dopamine and valproate administration in breast cancer patients
There is only indirect evidence available at present to suggest the role of prolactin (PRL) in either the promotion or progression of human breast cancer. In order to determine if dopaminergic and GABAergic regulation of PRL are similar in breast cancer patients, we studied 2 groups of premenopausal...
Gespeichert in:
| Veröffentlicht in: | Biomedicine & pharmacotherapy 1989, Vol.43 (4), p.301-306 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 306 |
|---|---|
| container_issue | 4 |
| container_start_page | 301 |
| container_title | Biomedicine & pharmacotherapy |
| container_volume | 43 |
| creator | Stalldecker, G.B. Pigni, J. Fuentes, A.M. Vegh, I. |
| description | There is only indirect evidence available at present to suggest the role of prolactin (PRL) in either the promotion or progression of human breast cancer. In order to determine if dopaminergic and GABAergic regulation of PRL are similar in breast cancer patients, we studied 2 groups of premenopausal women with no evident endocrine alteration : 1) control subjects (C); and 2) breast cancer patients (CA). Basal PRL levels were measured and their response to dopamine (DA) infusion (0.004 μg/kg/min) and valproate administration (400 mg/
p.o.). The mean of percentage inhibition by DA in C (
n=6) was significantly higher than in CA (
n=11) at 180 min;
P |
| doi_str_mv | 10.1016/0753-3322(89)90012-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79222419</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0753332289900127</els_id><sourcerecordid>79222419</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-b1b5309ea590db6103a304fa948087b85911aee788e97d47386ef732bd557d663</originalsourceid><addsrcrecordid>eNp9kE1rHDEMhk1pSbZp_0EDcwihPUwr2-OvSyCEfkGgOSRn47E14DI7ntjeQP99vd1ljz0JSc8rxEPIBwqfKVD5BZTgPeeMfdTmkwGgrFevyIYaAb0EUK_J5oSck7el_AYAIbk-I2dMgDQD25Cnh5xm52tcuoxlTUvBrqYupNVt44KdW0L34uY1J1dbF9owlppdjWnpWmjM6ErtvFs85m5tc1xqeUfeTG4u-P5YL8jTt6-Pdz_6-1_ff97d3veea1n7kY6Cg0EnDIRRUuCOwzA5M2jQatTCUOoQldZoVBhUC-GkOBuDECpIyS_I9eFu--95h6XabSwe59ktmHbFKsMYG6hp4HAAfU6lZJzsmuPW5T-Wgt3btHtVdq_KamP_2bSqxS6P93fjFsMpdNTX9lfHvSvezVNuGmI5YVJpBZQ37OaAYXPxEjHb4psnjyFm9NWGFP__x1_VxZCE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79222419</pqid></control><display><type>article</type><title>Prolactin response to dopamine and valproate administration in breast cancer patients</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Stalldecker, G.B. ; Pigni, J. ; Fuentes, A.M. ; Vegh, I.</creator><creatorcontrib>Stalldecker, G.B. ; Pigni, J. ; Fuentes, A.M. ; Vegh, I.</creatorcontrib><description>There is only indirect evidence available at present to suggest the role of prolactin (PRL) in either the promotion or progression of human breast cancer. In order to determine if dopaminergic and GABAergic regulation of PRL are similar in breast cancer patients, we studied 2 groups of premenopausal women with no evident endocrine alteration : 1) control subjects (C); and 2) breast cancer patients (CA). Basal PRL levels were measured and their response to dopamine (DA) infusion (0.004 μg/kg/min) and valproate administration (400 mg/
p.o.). The mean of percentage inhibition by DA in C (
n=6) was significantly higher than in CA (
n=11) at 180 min;
P<0.025. On the other hand, group C (
n=8) responded to valproate with maximal inhibition at 180min; in the CA group (
n=8) no inhibition was observed;
P < 0.0025.
Réponse de la prolactine à l'administration de la dopamine et du valproate chez des patientes atteintes de cancer du sein.
On ne dispose pour l'instant que d'arguments indirects en faveur d'un rôle de la prolactine (PRL) aussi bien dans la promotion du cancer du sein que dans son développement. Afin d'établir si les régulations dopaminergiques et gabaergique de la PRL sont ou non modifiées chez les malades atteintes de cancer du sein, les auteurs étudient deux groupes de femmes en période de préménopause et ne présentant pas de signe d'altération endocrinienne: un groupe de sujets-témoins (C) et un groupe de malades atteintes de cancer du sein (CA). Les auteurs ont mesuré les taux basals de PRL ainsi que la réponse obtenue après perfusion de dopamine (DA) à la dose de 0,004 μg/kg/min d'une part, et après administration de valproate (400mg per os) d'autre part.
La moyenne des pourcentages d'inhibition par la DA dans le groupe C (n=6) a été significativement plus élevé que dans le groupe CA (n =
11) à 180min; P<0,025. Par ailleurs, le groupe C (
n =8) a répondu au valproate avec une inhibition maximale à 180 min; alors que le groupe CA (n=8) n'a révélé aucune inhibition; P < 0.025
.</description><identifier>ISSN: 0753-3322</identifier><identifier>EISSN: 1950-6007</identifier><identifier>DOI: 10.1016/0753-3322(89)90012-7</identifier><identifier>PMID: 2506942</identifier><identifier>CODEN: BIPHEX</identifier><language>eng</language><publisher>Paris: Elsevier SAS</publisher><subject>Adult ; Antineoplastic agents ; Biological and medical sciences ; Breast Neoplasms - blood ; Breast Neoplasms - physiopathology ; Chemotherapy ; Dopamine - pharmacology ; dopamine / valproate / breast cancer ; dopamine / valproate / cancer du sein ; Female ; Humans ; Medical sciences ; Pharmacology. Drug treatments ; Prolactin - blood ; Time Factors ; Valproic Acid - pharmacology</subject><ispartof>Biomedicine & pharmacotherapy, 1989, Vol.43 (4), p.301-306</ispartof><rights>1989</rights><rights>1990 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c386t-b1b5309ea590db6103a304fa948087b85911aee788e97d47386ef732bd557d663</citedby><cites>FETCH-LOGICAL-c386t-b1b5309ea590db6103a304fa948087b85911aee788e97d47386ef732bd557d663</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/0753332289900127$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,4010,27900,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=6787013$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2506942$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stalldecker, G.B.</creatorcontrib><creatorcontrib>Pigni, J.</creatorcontrib><creatorcontrib>Fuentes, A.M.</creatorcontrib><creatorcontrib>Vegh, I.</creatorcontrib><title>Prolactin response to dopamine and valproate administration in breast cancer patients</title><title>Biomedicine & pharmacotherapy</title><addtitle>Biomed Pharmacother</addtitle><description>There is only indirect evidence available at present to suggest the role of prolactin (PRL) in either the promotion or progression of human breast cancer. In order to determine if dopaminergic and GABAergic regulation of PRL are similar in breast cancer patients, we studied 2 groups of premenopausal women with no evident endocrine alteration : 1) control subjects (C); and 2) breast cancer patients (CA). Basal PRL levels were measured and their response to dopamine (DA) infusion (0.004 μg/kg/min) and valproate administration (400 mg/
p.o.). The mean of percentage inhibition by DA in C (
n=6) was significantly higher than in CA (
n=11) at 180 min;
P<0.025. On the other hand, group C (
n=8) responded to valproate with maximal inhibition at 180min; in the CA group (
n=8) no inhibition was observed;
P < 0.0025.
Réponse de la prolactine à l'administration de la dopamine et du valproate chez des patientes atteintes de cancer du sein.
On ne dispose pour l'instant que d'arguments indirects en faveur d'un rôle de la prolactine (PRL) aussi bien dans la promotion du cancer du sein que dans son développement. Afin d'établir si les régulations dopaminergiques et gabaergique de la PRL sont ou non modifiées chez les malades atteintes de cancer du sein, les auteurs étudient deux groupes de femmes en période de préménopause et ne présentant pas de signe d'altération endocrinienne: un groupe de sujets-témoins (C) et un groupe de malades atteintes de cancer du sein (CA). Les auteurs ont mesuré les taux basals de PRL ainsi que la réponse obtenue après perfusion de dopamine (DA) à la dose de 0,004 μg/kg/min d'une part, et après administration de valproate (400mg per os) d'autre part.
La moyenne des pourcentages d'inhibition par la DA dans le groupe C (n=6) a été significativement plus élevé que dans le groupe CA (n =
11) à 180min; P<0,025. Par ailleurs, le groupe C (
n =8) a répondu au valproate avec une inhibition maximale à 180 min; alors que le groupe CA (n=8) n'a révélé aucune inhibition; P < 0.025
.</description><subject>Adult</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Breast Neoplasms - blood</subject><subject>Breast Neoplasms - physiopathology</subject><subject>Chemotherapy</subject><subject>Dopamine - pharmacology</subject><subject>dopamine / valproate / breast cancer</subject><subject>dopamine / valproate / cancer du sein</subject><subject>Female</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Prolactin - blood</subject><subject>Time Factors</subject><subject>Valproic Acid - pharmacology</subject><issn>0753-3322</issn><issn>1950-6007</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1989</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1rHDEMhk1pSbZp_0EDcwihPUwr2-OvSyCEfkGgOSRn47E14DI7ntjeQP99vd1ljz0JSc8rxEPIBwqfKVD5BZTgPeeMfdTmkwGgrFevyIYaAb0EUK_J5oSck7el_AYAIbk-I2dMgDQD25Cnh5xm52tcuoxlTUvBrqYupNVt44KdW0L34uY1J1dbF9owlppdjWnpWmjM6ErtvFs85m5tc1xqeUfeTG4u-P5YL8jTt6-Pdz_6-1_ff97d3veea1n7kY6Cg0EnDIRRUuCOwzA5M2jQatTCUOoQldZoVBhUC-GkOBuDECpIyS_I9eFu--95h6XabSwe59ktmHbFKsMYG6hp4HAAfU6lZJzsmuPW5T-Wgt3btHtVdq_KamP_2bSqxS6P93fjFsMpdNTX9lfHvSvezVNuGmI5YVJpBZQ37OaAYXPxEjHb4psnjyFm9NWGFP__x1_VxZCE</recordid><startdate>1989</startdate><enddate>1989</enddate><creator>Stalldecker, G.B.</creator><creator>Pigni, J.</creator><creator>Fuentes, A.M.</creator><creator>Vegh, I.</creator><general>Elsevier SAS</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>1989</creationdate><title>Prolactin response to dopamine and valproate administration in breast cancer patients</title><author>Stalldecker, G.B. ; Pigni, J. ; Fuentes, A.M. ; Vegh, I.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-b1b5309ea590db6103a304fa948087b85911aee788e97d47386ef732bd557d663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1989</creationdate><topic>Adult</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Breast Neoplasms - blood</topic><topic>Breast Neoplasms - physiopathology</topic><topic>Chemotherapy</topic><topic>Dopamine - pharmacology</topic><topic>dopamine / valproate / breast cancer</topic><topic>dopamine / valproate / cancer du sein</topic><topic>Female</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Prolactin - blood</topic><topic>Time Factors</topic><topic>Valproic Acid - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stalldecker, G.B.</creatorcontrib><creatorcontrib>Pigni, J.</creatorcontrib><creatorcontrib>Fuentes, A.M.</creatorcontrib><creatorcontrib>Vegh, I.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biomedicine & pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stalldecker, G.B.</au><au>Pigni, J.</au><au>Fuentes, A.M.</au><au>Vegh, I.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prolactin response to dopamine and valproate administration in breast cancer patients</atitle><jtitle>Biomedicine & pharmacotherapy</jtitle><addtitle>Biomed Pharmacother</addtitle><date>1989</date><risdate>1989</risdate><volume>43</volume><issue>4</issue><spage>301</spage><epage>306</epage><pages>301-306</pages><issn>0753-3322</issn><eissn>1950-6007</eissn><coden>BIPHEX</coden><abstract>There is only indirect evidence available at present to suggest the role of prolactin (PRL) in either the promotion or progression of human breast cancer. In order to determine if dopaminergic and GABAergic regulation of PRL are similar in breast cancer patients, we studied 2 groups of premenopausal women with no evident endocrine alteration : 1) control subjects (C); and 2) breast cancer patients (CA). Basal PRL levels were measured and their response to dopamine (DA) infusion (0.004 μg/kg/min) and valproate administration (400 mg/
p.o.). The mean of percentage inhibition by DA in C (
n=6) was significantly higher than in CA (
n=11) at 180 min;
P<0.025. On the other hand, group C (
n=8) responded to valproate with maximal inhibition at 180min; in the CA group (
n=8) no inhibition was observed;
P < 0.0025.
Réponse de la prolactine à l'administration de la dopamine et du valproate chez des patientes atteintes de cancer du sein.
On ne dispose pour l'instant que d'arguments indirects en faveur d'un rôle de la prolactine (PRL) aussi bien dans la promotion du cancer du sein que dans son développement. Afin d'établir si les régulations dopaminergiques et gabaergique de la PRL sont ou non modifiées chez les malades atteintes de cancer du sein, les auteurs étudient deux groupes de femmes en période de préménopause et ne présentant pas de signe d'altération endocrinienne: un groupe de sujets-témoins (C) et un groupe de malades atteintes de cancer du sein (CA). Les auteurs ont mesuré les taux basals de PRL ainsi que la réponse obtenue après perfusion de dopamine (DA) à la dose de 0,004 μg/kg/min d'une part, et après administration de valproate (400mg per os) d'autre part.
La moyenne des pourcentages d'inhibition par la DA dans le groupe C (n=6) a été significativement plus élevé que dans le groupe CA (n =
11) à 180min; P<0,025. Par ailleurs, le groupe C (
n =8) a répondu au valproate avec une inhibition maximale à 180 min; alors que le groupe CA (n=8) n'a révélé aucune inhibition; P < 0.025
.</abstract><cop>Paris</cop><pub>Elsevier SAS</pub><pmid>2506942</pmid><doi>10.1016/0753-3322(89)90012-7</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0753-3322 |
| ispartof | Biomedicine & pharmacotherapy, 1989, Vol.43 (4), p.301-306 |
| issn | 0753-3322 1950-6007 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79222419 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Antineoplastic agents Biological and medical sciences Breast Neoplasms - blood Breast Neoplasms - physiopathology Chemotherapy Dopamine - pharmacology dopamine / valproate / breast cancer dopamine / valproate / cancer du sein Female Humans Medical sciences Pharmacology. Drug treatments Prolactin - blood Time Factors Valproic Acid - pharmacology |
| title | Prolactin response to dopamine and valproate administration in breast cancer patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T01%3A43%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prolactin%20response%20to%20dopamine%20and%20valproate%20administration%20in%20breast%20cancer%20patients&rft.jtitle=Biomedicine%20&%20pharmacotherapy&rft.au=Stalldecker,%20G.B.&rft.date=1989&rft.volume=43&rft.issue=4&rft.spage=301&rft.epage=306&rft.pages=301-306&rft.issn=0753-3322&rft.eissn=1950-6007&rft.coden=BIPHEX&rft_id=info:doi/10.1016/0753-3322(89)90012-7&rft_dat=%3Cproquest_cross%3E79222419%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79222419&rft_id=info:pmid/2506942&rft_els_id=0753332289900127&rfr_iscdi=true |